Tech giant Microsoft is growing its presence in the pharmaceutical space. We dig into its strategy here.
Pharmaceutical companies are working to create drugs for more targeted patient populations based on genetics, demographics, or disease states instead of broad groups. But this method requires using AI and analytics tech to parse through huge amounts of data, and most pharma companies aren’t equipped to execute on their own.
This presents a massive opportunity for big tech companies. Drug discovery technology is a $120B market, and corporate executives are beginning to notice.
Microsoft has already embarked on a number of initiatives in the space. For example, it’s working with Novartis to apply generative AI for drug discovery, and collaborating with Verily to deploy an open access biomedical research platform on the Azure cloud.
Below, we examine how Microsoft is applying its data security, accessibility, and analytics capabilities to drug discovery and clinical research.
